The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
Delfi Diagnostics
Develops liquid biopsy tests using fragmentomics to detect lung and other cancers early.
What they do
Delfi Diagnostics develops next-generation liquid biopsy tests utilizing fragmentomics, which analyzes cell-free DNA packaging patterns in blood. The company sells these high-performance, cost-effective screening solutions to clinical laboratories and healthcare systems to detect multiple cancer types at their earliest stages.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- Baltimore, United States
- Region
- North America
- Founded
- 2019
- Total funding
- $335M raised
Notable investors: OrbiMed, Cowen Healthcare Investments, F-Prime Capital, Eli Lilly and Company.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The barbershop health screening model is expanding well beyond blood pressure
Dr. Dereck Mush, MD, MBA
Screening Programs Are Rebuilding Around Reminder Systems That Actually Reach People
Dr. Dereck Mush, MD, MBA
PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA